exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Company profile
Ticker
EXEL
Exchange
Website
CEO
Michael M. Morrissey
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EXELIXIS INC
SEC CIK
Corporate docs
Subsidiaries
Exelixis Patent Company, LLC • Exelixis Plant Sciences, Inc. • Exelixis U.S., LLC ...
IRS number
43257395
EXEL stock data
Latest filings (excl ownership)
8-K
Other Events
20 May 24
8-K
Other Events
10 May 24
10-Q
2024 Q1
Quarterly report
30 Apr 24
8-K
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
30 Apr 24
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
10-K
2023 FY
Annual report
6 Feb 24
8-K
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
6 Feb 24
Transcripts
EXEL
Earnings call transcript
2024 Q1
30 Apr 24
EXEL
Earnings call transcript
2023 Q4
6 Feb 24
EXEL
Earnings call transcript
2023 Q3
1 Nov 23
EXEL
Earnings call transcript
2023 Q2
1 Aug 23
EXEL
Earnings call transcript
2023 Q1
9 May 23
EXEL
Earnings call transcript
2022 Q4
7 Feb 23
EXEL
Earnings call transcript
2022 Q3
2 Nov 22
EXEL
Earnings call transcript
2022 Q2
10 Aug 22
EXEL
Earnings call transcript
2022 Q1
11 May 22
EXEL
Earnings call transcript
2021 Q4
18 Feb 22
Latest ownership filings
4
DAVID EDWARD JOHNSON
30 May 24
4
Julie Smith
23 May 24
4
GEORGE POSTE
22 May 24
4
STELIOS PAPADOPOULOS
22 May 24
144
Notice of proposed sale of securities
21 May 24
144
Notice of proposed sale of securities
20 May 24
4
MICHAEL MORRISSEY
17 May 24
4
Dana Aftab
17 May 24
4
Patrick J. Haley
17 May 24
4
Jeffrey Hessekiel
17 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Jan 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 259.56 mm | 259.56 mm | 259.56 mm | 259.56 mm | 259.56 mm | 259.56 mm |
Cash burn (monthly) | 1.14 mm | 23.54 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 2.44 mm | 50.24 mm | n/a | n/a | n/a | n/a |
Cash remaining | 257.12 mm | 209.32 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 224.7 | 8.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
18.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 158 |
Opened positions | 36 |
Closed positions | 196 |
Increased positions | 34 |
Reduced positions | 53 |
13F shares | Current |
---|---|
Total value | 535.21 bn |
Total shares | 53.24 mm |
Total puts | 302.70 k |
Total calls | 496.50 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Farallon Capital Partners | 24.91 mm | $480.35 mm |
BK Bank Of New York Mellon | 2.78 mm | $65.86 bn |
LSV Asset Management | 2.77 mm | $65.84 mm |
Los Angeles Capital Management & Equity Research | 2.45 mm | $58.24 bn |
Meditor | 2.20 mm | $52.18 bn |
California Public Employees Retirement System | 1.94 mm | $45.94 bn |
Assenagon Asset Management | 1.77 mm | $41.92 bn |
Russell Investments | 1.53 mm | $36.42 bn |
Allspring Global Investments | 1.28 mm | $30.35 bn |
PFG Principal Financial Group Inc - Registered Shares | 1.15 mm | $27.20 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 May 24 | Johnson David Edward | Common Stock | Buy | Acquire P | Yes | No | 20.7558 | 225,000 | 4.67 mm | 1,525,730 |
28 May 24 | Johnson David Edward | Common Stock | Buy | Acquire P | Yes | No | 20.3195 | 200,000 | 4.06 mm | 1,300,730 |
21 May 24 | Poste George | Common Stock | Sell | Dispose S | No | No | 20.96 | 11,686 | 244.94 k | 213,907 |
21 May 24 | Poste George | Common Stock | Option exercise | Acquire M | No | No | 19.57 | 11,686 | 228.70 k | 225,593 |
21 May 24 | Poste George | Option Common Stock | Option exercise | Dispose M | No | No | 19.57 | 11,686 | 228.70 k | 0 |
21 May 24 | Smith Julie | Common Stock | Sell | Dispose S | No | No | 21.12 | 27,280 | 576.15 k | 5,445 |
20 May 24 | Papadopoulos Stelios | Common Stock | Sell | Dispose S | No | No | 21 | 11,437 | 240.18 k | 1,260,578 |
20 May 24 | Papadopoulos Stelios | Common Stock | Option exercise | Acquire M | No | No | 19.57 | 11,686 | 228.70 k | 1,272,015 |
20 May 24 | Papadopoulos Stelios | Option Common Stock | Option exercise | Dispose M | No | No | 19.57 | 11,686 | 228.70 k | 0 |
15 May 24 | Haley Patrick J. | Common Stock | Payment of exercise | Dispose F | No | No | 20.99 | 10,101 | 212.02 k | 355,036 |
News
10 Health Care Stocks Whale Activity In Today's Session
31 May 24
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
31 May 24
Stephens & Co. Initiates Coverage On Exelixis with Equal-Weight Rating, Announces Price Target of $23
14 May 24
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
10 May 24
HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $28 Price Target
3 May 24
Press releases
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
28 May 24
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
20 May 24
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
16 Apr 24